A Clinical Trial to Assess the Pharmacokinetics and Safety of AD-229 Compared to AD-2291 in Healthy Adults
ConditionGastritis
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age19+
SponsorAddpharma Inc.
About this trial
The study compare and evaluate the safety and pharmacokinetic characteristics between the administration of AD-229 and the administration of AD-2291 in healthy adults.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Body mass index (BMI) between 18.5 kg/m2 and 29.9 kg/m2 at the time of screening visit
The Age equal to or greater than 19 in healthy volunteers at the time of screening visit
Disqualifiers
Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
Other exclusions applied
Trial design
Design model
Crossover
Treatments tested in this trial
AD-229
DrugAD-229 Oral Tablet
AD-2291
DrugAD-2291 Oral Tablet
Treatment groups
28 Participants
are divided into 2 treatment groupsGroup A: Sequence AExperimental treatment 2 interventions
Group B: Sequence BExperimental treatment 2 interventions
Trial outcomes
Primary outcomes
1
Maximum concentration of drug in plasma (Cmax)
Cmax of AD-229
Time frame
pre-dose (0hour) to 72hours2
Area under the plasma concentration-time curve during dosing interval (AUCt)
AUCt of AD-229
Time frame
pre-dose (0hour) to 72hoursLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: